The ascendancy of Viagra and its effect on the pharmaceutical landscape presents a intricate question for investors. While the initial sales data were astounding, the patent has lapsed, leading to a wave of generic alternatives that are chipping away at profit. Furthermore, the industry is facing issues related to aging trends and changing healt… Read More